Knight Therapeuticsの資産のリターン
Knight Therapeuticsの資産のリターン は何ですか。
Knight Therapeutics, Inc.の資産のリターン は-2.19%です。
資産のリターン の定義は何ですか。
資産のリターンは 、企業の資産が収益を生み出す際の収益性を示します。純利益を平均総資産で除して計算されます。
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
TSXのセクタHealth Careにおける資産のリターン の企業と比べるKnight Therapeutics
Knight Therapeuticsは何をしますか。
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Knight Therapeuticsと類似の資産のリターン
- Ares Commercial Real Estate Corpの資産のリターン は-2.21%です。
- Hind Aluminium Industriesの資産のリターン は-2.21%です。
- VIVUSの資産のリターン は-2.20%です。
- Maiden Ltdの資産のリターン は-2.20%です。
- Threat Protect Australiaの資産のリターン は-2.20%です。
- Ganesh Housingの資産のリターン は-2.20%です。
- Knight Therapeuticsの資産のリターン は-2.19%です。
- Syschem (India)の資産のリターン は-2.19%です。
- Newell Brands Incの資産のリターン は-2.19%です。
- Newell Brandsの資産のリターン は-2.19%です。
- Natural Alternatives Internationalの資産のリターン は-2.19%です。
- Daxorの資産のリターン は-2.19%です。
- Global Vanadiumの資産のリターン は-2.19%です。